Resp - Lung cancer

Question 1

Lung Cancer

Histological subtypes
Comparison between SCLC and NSCLC

Answer 1

SCLC (5-10%)

NSCLC:
- Large cell carcinoma (5-10%)
- Adenocarcinoma (45-55%)
- Squamous cell carcinoma (20-30%)

Question 2

Lung cancer

Route of spread

Answer 2

Question 3

Lung Cancer

Epidemiology

Answer 3

Question 4

Lung Cancer

Reasons of high lung cancer prevalence in Asian female non-smokers

Answer 4

Question 5

Lung Cancer

Causes

Answer 5

Question 6

Lung cancer

Pathogenesis

Answer 6

Question 7

Lung Cancer

Key genetic mutations

Answer 7

Question 8

Lung Cancer

Local symptoms

Answer 8

Question 9

Lung Cancer

Paraneoplastic syndrome

Answer 9

Question 10

Lung Cancer

Systemic syndromes

Answer 10

Question 11

Lung Cancer

P/E

Answer 11

Question 12

Lung Cancer

Biochemical Ix

Answer 12

Question 13

Lung Cancer

Radiological Ix

Answer 13

Question 14

Lung Cancer

Genetic testing
- Rationale
- Indications
- Common mutations
- Timing for testing
- Sample collection

Answer 14

Question 15

Lung Cancer

Genetic testing pitfalls

Answer 15

Question 16

Lung Cancer

Outline treatment options for diff. histological subtypes

Answer 16

Question 17

Targeted therapy options for NSCLC

Answer 17

Question 18

Lung cancer

Medical treatment options: chemotherapy and targeted therapy

Answer 18

Question 19

Lung cancer

Immunotherapy options

Answer 19

Question 20

causes of hyponatremia in CA lung patients

Answer 20

 Syndrome of inappropriate ADH (Most common)
 Depletional hyponatremia due to poor oral intake
 Cortisol insufficiency due to bilateral adrenal metastasis

Question 21

Treatment of lung cancer brain metastasis

Answer 21

Question 22

Secondary lung tumour

Source of tumour/ common primaries
Imaging feature
Management

Answer 22

Question 23

Lymphangitis carcinomatosis

Common primaries
Imaging
Management

Answer 23

Question 24

SCLC

Treatment for limited stage disease, unresectable stage disease and extensive stage disease

Answer 24

Question 25

EGFR actionable mutations (exon 19 deletion, L858R mutation) lung cancer

Treatment options
Side effects
Resistance pattern

Answer 25

Question 26

ALK translocation/ ROS1 rearrangement lung cancer

Treatment option
Side effects
Resistance pattern

Answer 26

Question 27

PD-LI expression lung cancer

Treatment option
Side effect

Answer 27

Question 28

NSCLC

Treatment outline

Answer 28

Question 29

Lung Cancer

Surgical treatment option for resectable NSCLC

Answer 29

Question 30

Lung Cancer

Criteria for resectable NSCLC

Answer 30

Question 31

Lung cancer

Tissue diagnosis methods

Answer 31

Question 32

Lung cancer

Radiological presentations

Answer 32